IGC Pharma, Inc. (IGC)
NYSEAMERICAN: IGC · Real-Time Price · USD
0.3090
-0.0010 (-0.32%)
At close: Jun 27, 2025, 4:00 PM
0.3199
+0.0109 (3.53%)
After-hours: Jun 27, 2025, 8:00 PM EDT
IGC Pharma Revenue
In the fiscal year ending March 31, 2025, IGC Pharma had annual revenue of $1.27M, down -5.50%. IGC Pharma had revenue of $330.00K in the quarter ending March 31, 2025, with 11.86% growth.
Revenue (ttm)
$1.27M
Revenue Growth
-5.50%
P/S Ratio
18.60
Revenue / Employee
$18,970
Employees
67
Market Cap
24.62M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 1.27M | -74.00K | -5.50% |
| Mar 31, 2024 | 1.35M | 434.00K | 47.64% |
| Mar 31, 2023 | 911.00K | 514.00K | 129.47% |
| Mar 31, 2022 | 397.00K | -501.00K | -55.79% |
| Mar 31, 2021 | 898.00K | -3.17M | -77.95% |
| Mar 31, 2020 | Pro | Pro | Pro |
| Mar 31, 2019 | Pro | Pro | Pro |
| Mar 31, 2018 | Pro | Pro | Pro |
| Mar 31, 2017 | Pro | Pro | Pro |
| Mar 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
IGC News
- 15 hours ago - IGC Pharma to Host Fiscal Year-End 2025 Shareholder Update Call on Monday June 30, 2025 - Accesswire
- 4 days ago - IGC Pharma Expands CALMA Trial to Oklahoma, Partnering with Dr. David McCoy at Tekton Research in Yukon - Accesswire
- 5 weeks ago - IGC Pharma's Puerto Rico CALMA Trial Site Offers Strategic Opportunity in High-Prevalence Alzheimer's Market - Accesswire
- 6 weeks ago - IGC Pharma Presents Genetic Toxicology Safety Data on API in IGC-AD1, at the 2025 Genetic Toxicology Association Meeting - Accesswire
- 2 months ago - IGC Pharma Welcomes Strategic Investment from Advisors - Accesswire
- 2 months ago - IGC Pharma Welcomes Industry Leaders to Advisory Board, Supporting Alzheimer's Innovation and AI-Driven Programs - Accesswire
- 2 months ago - IGC Pharma Expands CALMA Alzheimer's Phase 2 Trial with Prestigious Research Site at Butler Hospital's Memory and Aging Program - Accesswire
- 3 months ago - IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish Health - Accesswire